An article suggests that the next billion-dollar longevity opportunity may not be a product. While longevity has ample products, science, capital, and consumer interest, the bottleneck is translation: getting promising science validated, understood by clinicians, implemented responsibly, and ultimately to patients.
Related Articles
Don't miss out on breaking stories and in-depth articles.